{"id":21082,"date":"2025-01-09T20:48:04","date_gmt":"2025-01-09T12:48:04","guid":{"rendered":"https:\/\/flcube.com\/?p=21082"},"modified":"2025-01-09T20:48:07","modified_gmt":"2025-01-09T12:48:07","slug":"araris-biotech-and-chugai-pharmaceutical-collaborate-on-novel-adc-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21082","title":{"rendered":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development"},"content":{"rendered":"\n<p>Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris&#8217; proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.<\/p>\n\n\n\n<p><strong>Deal Terms and Financials<\/strong><br>Under the agreement, Chugai will pay an upfront fee and fund all research activities. After exercising the option, Chugai will be solely responsible for the development, manufacturing, and global commercialization activities. Araris will be eligible for potential milestone payments of approximately USD 780 million, plus royalties on net sales of products, upon Chugai&#8217;s achievement of certain development, regulatory, and commercial milestones.<\/p>\n\n\n\n<p><strong>Significance of the Collaboration<\/strong><br>This collaboration between Araris Biotech and Chugai Pharmaceutical underscores the growing interest in developing innovative ADCs for oncology. By leveraging Araris&#8217; AraLinQ platform, the partnership aims to accelerate the discovery and development of novel therapies, potentially improving treatment options for patients with various cancers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license&#8230;<\/p>\n","protected":false},"author":1,"featured_media":21083,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,3100,382],"class_list":["post-21082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-araris-biotech","tag-chugai-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris&#039; proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21082\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development\" \/>\n<meta property=\"og:description\" content=\"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris&#039; proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21082\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T12:48:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T12:48:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"625\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development\",\"datePublished\":\"2025-01-09T12:48:04+00:00\",\"dateModified\":\"2025-01-09T12:48:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082\"},\"wordCount\":174,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0908.png\",\"keywords\":[\"ADC \\\/ XDC\",\"Araris Biotech\",\"Chugai Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21082#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21082\",\"name\":\"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0908.png\",\"datePublished\":\"2025-01-09T12:48:04+00:00\",\"dateModified\":\"2025-01-09T12:48:07+00:00\",\"description\":\"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris' proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21082\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0908.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0908.png\",\"width\":1080,\"height\":625,\"caption\":\"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21082#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development - Insight, China&#039;s Pharmaceutical Industry","description":"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris' proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21082","og_locale":"en_US","og_type":"article","og_title":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development","og_description":"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris' proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.","og_url":"https:\/\/flcube.com\/?p=21082","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T12:48:04+00:00","article_modified_time":"2025-01-09T12:48:07+00:00","og_image":[{"width":1080,"height":625,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21082#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21082"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development","datePublished":"2025-01-09T12:48:04+00:00","dateModified":"2025-01-09T12:48:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21082"},"wordCount":174,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21082#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","keywords":["ADC \/ XDC","Araris Biotech","Chugai Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21082#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21082","url":"https:\/\/flcube.com\/?p=21082","name":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21082#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21082#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","datePublished":"2025-01-09T12:48:04+00:00","dateModified":"2025-01-09T12:48:07+00:00","description":"Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris' proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21082#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21082"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21082#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","width":1080,"height":625,"caption":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21082#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0908.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21082"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21082\/revisions"}],"predecessor-version":[{"id":21084,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21082\/revisions\/21084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21083"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}